Cargando…

Proteomics of serum exosomes identified fibulin-1 as a novel biomarker for mild cognitive impairment

Mild cognitive impairment (MCI) is a prodrome of Alzheimer’s disease pathology. Cognitive impairment patients often have a delayed diagnosis because there are no early symptoms or conventional diagnostic methods. Exosomes play a vital role in cell-to-cell communications and can act as promising biom...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Bo, Song, Li, Yang, Juan, Zhou, Wei-Ying, Cheng, Yuan-Yuan, Lai, Yu-Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727429/
https://www.ncbi.nlm.nih.gov/pubmed/36018182
http://dx.doi.org/10.4103/1673-5374.347740
_version_ 1784845017416728576
author Chen, Bo
Song, Li
Yang, Juan
Zhou, Wei-Ying
Cheng, Yuan-Yuan
Lai, Yu-Jie
author_facet Chen, Bo
Song, Li
Yang, Juan
Zhou, Wei-Ying
Cheng, Yuan-Yuan
Lai, Yu-Jie
author_sort Chen, Bo
collection PubMed
description Mild cognitive impairment (MCI) is a prodrome of Alzheimer’s disease pathology. Cognitive impairment patients often have a delayed diagnosis because there are no early symptoms or conventional diagnostic methods. Exosomes play a vital role in cell-to-cell communications and can act as promising biomarkers in diagnosing diseases. This study was designed to identify serum exosomal candidate proteins that may play roles in diagnosing MCI. Mass spectrometry coupled with tandem mass tag approach-based non-targeted proteomics was used to show the differentially expressed proteins in exosomes between MCI patients and healthy controls, and these differential proteins were validated using immunoblot and enzyme-linked immunosorbent assays. Correlation of cognitive performance with the serum exosomal protein level was determined. Nanoparticle tracking analysis suggested that there was a higher serum exosome concentration and smaller exosome diameter in individuals with MCI compared with healthy controls. We identified 69 exosomal proteins that were differentially expressed between MCI patients and healthy controls using mass spectrometry analysis. Thirty-nine exosomal proteins were upregulated in MCI patients compared with those in control patients. Exosomal fibulin-1, with an area under the curve value of 0.81, may be a biomarker for an MCI diagnosis. The exosomal protein signature from MCI patients reflected the cell adhesion molecule category. In particular, higher exosomal fibulin-1 levels correlated with lower cognitive performance. Thus, this study revealed that exosomal fibulin-1 is a promising biomarker for diagnosing MCI.
format Online
Article
Text
id pubmed-9727429
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-97274292022-12-08 Proteomics of serum exosomes identified fibulin-1 as a novel biomarker for mild cognitive impairment Chen, Bo Song, Li Yang, Juan Zhou, Wei-Ying Cheng, Yuan-Yuan Lai, Yu-Jie Neural Regen Res Research Article Mild cognitive impairment (MCI) is a prodrome of Alzheimer’s disease pathology. Cognitive impairment patients often have a delayed diagnosis because there are no early symptoms or conventional diagnostic methods. Exosomes play a vital role in cell-to-cell communications and can act as promising biomarkers in diagnosing diseases. This study was designed to identify serum exosomal candidate proteins that may play roles in diagnosing MCI. Mass spectrometry coupled with tandem mass tag approach-based non-targeted proteomics was used to show the differentially expressed proteins in exosomes between MCI patients and healthy controls, and these differential proteins were validated using immunoblot and enzyme-linked immunosorbent assays. Correlation of cognitive performance with the serum exosomal protein level was determined. Nanoparticle tracking analysis suggested that there was a higher serum exosome concentration and smaller exosome diameter in individuals with MCI compared with healthy controls. We identified 69 exosomal proteins that were differentially expressed between MCI patients and healthy controls using mass spectrometry analysis. Thirty-nine exosomal proteins were upregulated in MCI patients compared with those in control patients. Exosomal fibulin-1, with an area under the curve value of 0.81, may be a biomarker for an MCI diagnosis. The exosomal protein signature from MCI patients reflected the cell adhesion molecule category. In particular, higher exosomal fibulin-1 levels correlated with lower cognitive performance. Thus, this study revealed that exosomal fibulin-1 is a promising biomarker for diagnosing MCI. Wolters Kluwer - Medknow 2022-08-02 /pmc/articles/PMC9727429/ /pubmed/36018182 http://dx.doi.org/10.4103/1673-5374.347740 Text en Copyright: © Neural Regeneration Research https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Research Article
Chen, Bo
Song, Li
Yang, Juan
Zhou, Wei-Ying
Cheng, Yuan-Yuan
Lai, Yu-Jie
Proteomics of serum exosomes identified fibulin-1 as a novel biomarker for mild cognitive impairment
title Proteomics of serum exosomes identified fibulin-1 as a novel biomarker for mild cognitive impairment
title_full Proteomics of serum exosomes identified fibulin-1 as a novel biomarker for mild cognitive impairment
title_fullStr Proteomics of serum exosomes identified fibulin-1 as a novel biomarker for mild cognitive impairment
title_full_unstemmed Proteomics of serum exosomes identified fibulin-1 as a novel biomarker for mild cognitive impairment
title_short Proteomics of serum exosomes identified fibulin-1 as a novel biomarker for mild cognitive impairment
title_sort proteomics of serum exosomes identified fibulin-1 as a novel biomarker for mild cognitive impairment
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727429/
https://www.ncbi.nlm.nih.gov/pubmed/36018182
http://dx.doi.org/10.4103/1673-5374.347740
work_keys_str_mv AT chenbo proteomicsofserumexosomesidentifiedfibulin1asanovelbiomarkerformildcognitiveimpairment
AT songli proteomicsofserumexosomesidentifiedfibulin1asanovelbiomarkerformildcognitiveimpairment
AT yangjuan proteomicsofserumexosomesidentifiedfibulin1asanovelbiomarkerformildcognitiveimpairment
AT zhouweiying proteomicsofserumexosomesidentifiedfibulin1asanovelbiomarkerformildcognitiveimpairment
AT chengyuanyuan proteomicsofserumexosomesidentifiedfibulin1asanovelbiomarkerformildcognitiveimpairment
AT laiyujie proteomicsofserumexosomesidentifiedfibulin1asanovelbiomarkerformildcognitiveimpairment